First BTK Inhibitor Approved for Immune Thrombocytopenia

(Medage today) – The FDA approved the oral rilzabrutinib (Wayrilz) for treating persistent or chronic immune thrombocytopenia (ITP), the agency announced on Tuesday. Like the first inhibitor of the Tyrosine Kinase de Bruton (BTK) for ITP, the indication stipulates …